Several challenges exist in the use of HDACi in pediatrics. One major challenge is the lack of extensive clinical trials focusing specifically on children. Pediatric patients are not just small adults; their metabolic and pharmacokinetic profiles can differ significantly, necessitating tailored dosing and monitoring protocols. Additionally, the long-term effects of HDACi on developing tissues and organs are not fully understood, raising concerns about potential adverse outcomes.
